CAP-100
CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL[1].
Product Specifications
UNSPSC
12352203
Target
CCR
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Purity
99.84
Smiles
[CAP-100]
Molecular Weight
(146.48 kDa)
References & Citations
[1]Cuesta-Mateos C, et al., Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. MAbs. 2021 Jan-Dec;13 (1) :1917484.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
133892-ML490 100 µL
ST3GAL1 (ST3O, Sialyltransferase 4A, SIAT4-A, SIAT4, SIAT4A, Alpha 2,3-ST 1, Beta-galactoside alpha-2,3-sialyltransferase 1, Gal-NAc6S, SIATFL, ST3Gal I, ST3GalI, ST3GalA.1, CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1, DKFZp666E036, DKFZp779K2051, FLJ36548, MGC9183, Gal-beta-1,3-GalNAc-alpha-2,3-sialyltransferase) (MaxLight 490)
Sign In for Pricing
View Details MBS9907075-01 48 Well
Monkey Forkhead-Associated Domain-Containing Protein 1 (FHAD1) ELISA Kit
Sign In for Pricing
View Details MBS9907075-02 96 Well
Monkey Forkhead-Associated Domain-Containing Protein 1 (FHAD1) ELISA Kit
Sign In for Pricing
View Details